131 related articles for article (PubMed ID: 9175618)
1. The effects of cholecystokinin A and B receptor antagonists on exploratory behaviour in the elevated zero-maze in rat.
Matto V; Harro J; Allikmets L
Neuropharmacology; 1997 Mar; 36(3):389-96. PubMed ID: 9175618
[TBL] [Abstract][Full Text] [Related]
2. The effects of cholecystokinin A and B receptor antagonists, devazepide and L 365260, on citalopram-induced decrease of exploratory behaviour in rat.
Matto V; Harro J; Allikmets L
J Physiol Pharmacol; 1996 Dec; 47(4):661-9. PubMed ID: 9116333
[TBL] [Abstract][Full Text] [Related]
3. The benzodiazepine antagonist flumazenil blocks the effects of CCK receptor agonists and antagonists in the elevated plus-maze.
Chopin P; Briley M
Psychopharmacology (Berl); 1993; 110(4):409-14. PubMed ID: 7870910
[TBL] [Abstract][Full Text] [Related]
4. 'Anxiolytic' effect of CCK-antagonists on plus-maze behavior in mice.
Rataud J; Darche F; Piot O; Stutzmann JM; Böhme GA; Blanchard JC
Brain Res; 1991 May; 548(1-2):315-7. PubMed ID: 1868342
[TBL] [Abstract][Full Text] [Related]
5. Opposite effects mediated by CCKA and CCKB receptors in behavioural and hormonal studies in rats.
Männistö PT; Lang A; Harro J; Peuranen E; Bradwejn J; Vasar E
Naunyn Schmiedebergs Arch Pharmacol; 1994 May; 349(5):478-84. PubMed ID: 8065461
[TBL] [Abstract][Full Text] [Related]
6. The influence of 5-hydroxytryptamine re-uptake blockade on CCK receptor antagonist effects in the rat elevated zero-maze.
Bickerdike MJ; Marsden CA; Dourish CT; Fletcher A
Eur J Pharmacol; 1994 Dec; 271(2-3):403-11. PubMed ID: 7705440
[TBL] [Abstract][Full Text] [Related]
7. The effect of drugs acting on CCK receptors and rat free exploration in the exploration box.
Matto V; Harro J; Allikmets L
J Physiol Pharmacol; 1997 Jun; 48(2):239-51. PubMed ID: 9223028
[TBL] [Abstract][Full Text] [Related]
8. The effects of CCK-4 on dopamine D1 agonist-induced grooming are blocked by a CCK(A) receptor antagonist: evidence for a novel CCK receptor subtype?
van Kampen J; Stoessl AJ
Neuropharmacology; 1997; 36(11-12):1679-88. PubMed ID: 9517439
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological evaluation of IQM-95,333, a highly selective CCKA receptor antagonist with anxiolytic-like activity in animal models.
Ballaz S; Barber A; Fortuño A; Del Río J; Martin-Martínez M; Gómez-Monterrey I; Herranz R; González-Muñiz R; García-López MT
Br J Pharmacol; 1997 Jun; 121(4):759-67. PubMed ID: 9208145
[TBL] [Abstract][Full Text] [Related]
10. BOC-CCK-4, CCK(B)receptor agonist, antagonizes anxiolytic-like action of morphine in elevated plus-maze.
Kõks S; Soosaar A; Võikar V; Bourin M; Vasar E
Neuropeptides; 1999 Feb; 33(1):63-9. PubMed ID: 10657473
[TBL] [Abstract][Full Text] [Related]
11. Anti-exploratory effect of N-methyl-D-aspartate in elevated plus-maze. Involvement of NMDA and CCK receptors.
Vasar E; Harro J; Lang A; Soosaar A; Oöpik T; Kôks S; Sihver S; Volke V
Eur Neuropsychopharmacol; 1993 Mar; 3(1):63-73. PubMed ID: 8471831
[TBL] [Abstract][Full Text] [Related]
12. Evidence for potentiation by CCK antagonists of the effect of cholecystokinin octapeptide in the elevated plus-maze.
Vasar E; Lang A; Harro J; Bourin M; Bradwejn J
Neuropharmacology; 1994 Jun; 33(6):729-35. PubMed ID: 7936110
[TBL] [Abstract][Full Text] [Related]
13. CCK(B) antagonists protect against anxiety-related behaviour produced by ethanol withdrawal, measured using the elevated plus maze.
Wilson J; Watson WP; Little HJ
Psychopharmacology (Berl); 1998 May; 137(2):120-31. PubMed ID: 9629998
[TBL] [Abstract][Full Text] [Related]
14. The gerbil elevated plus-maze I: behavioral characterization and pharmacological validation.
Varty GB; Morgan CA; Cohen-Williams ME; Coffin VL; Carey GJ
Neuropsychopharmacology; 2002 Sep; 27(3):357-70. PubMed ID: 12225693
[TBL] [Abstract][Full Text] [Related]
15. CR 2945: a novel CCKB receptor antagonist with anxiolytic-like activity.
Revel L; Mennuni L; Garofalo P; Makovec F
Behav Pharmacol; 1998 May; 9(3):183-94. PubMed ID: 9832933
[TBL] [Abstract][Full Text] [Related]
16. Lack of effect of CCKB receptor antagonists in ethological and conditioned animal screens for anxiolytic drugs.
Dawson GR; Rupniak NM; Iversen SD; Curnow R; Tye S; Stanhope KJ; Tricklebank MD
Psychopharmacology (Berl); 1995 Sep; 121(1):109-17. PubMed ID: 8539335
[TBL] [Abstract][Full Text] [Related]
17. Neurobehavioural effects of SR 27897, a selective cholecystokinin type A (CCK-A) receptor antagonist.
Poncelet M; Arnone M; Heaulme M; Gonalons N; Gueudet C; Santucci V; Thurneyssen O; Keane P; Gully D; Le Fur G
Naunyn Schmiedebergs Arch Pharmacol; 1993 Jul; 348(1):102-7. PubMed ID: 8397341
[TBL] [Abstract][Full Text] [Related]
18. Analysis of strain difference in behavior to Cholecystokinin (CCK) receptor mediated drugs in PVG hooded and Sprague-Dawley rats using elevated plus-maze test apparatus.
Farook JM; Zhu YZ; Wang Q; Moochhala SM; Lee L; Wong PT
Neurosci Lett; 2004 Apr; 358(3):215-9. PubMed ID: 15039119
[TBL] [Abstract][Full Text] [Related]
19. Cholecystokinin-induced anxiety in rats: relevance of pre-experimental stress and seasonal variations.
Kõks S; Männistö PT; Bourin M; Shlik J; Vasar V; Vasar E
J Psychiatry Neurosci; 2000 Jan; 25(1):33-42. PubMed ID: 10721682
[TBL] [Abstract][Full Text] [Related]
20. Reactivation of cocaine conditioned place preference induced by stress is reversed by cholecystokinin-B receptors antagonist in rats.
Lu L; Zhang B; Liu Z; Zhang Z
Brain Res; 2002 Nov; 954(1):132-40. PubMed ID: 12393241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
